Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead Sciences is preparing to file for approval of its single-tablet anti-retroviral therapy (ART) combination in human immunodeficiency virus (HIV)…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Novartis to seek approval of anti-malaria drug on Phase III success
Novartis’ anti-malaria drug could mark the first major advancement in more than 25 years after it showed non-inferiority in a…
-
EuropaBio calls for “bold approach to investment” amid EU Biotech Act
Amid the European Commission’s (EC’s) public consultation on the EU Biotech Act, EuropaBio has called for the EU to adopt…
-
Narcolepsy race heats up with Alkermes’ OX2R NT2 data but investors spooked
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has met its dual primary endpoints in the high doses in a…
-
UK invests £60m to phase out animal testing in preclinical trials
The UK Government is investing £60m ($78.76m) to push pharma and biotech to use alternative preclinical models in a pull…
-
enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial
enGene’s gene therapy for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has touted a 63% complete response (CR)…
-
Cogent’s stock soars on Phase III gastrointestinal cancer data
Cogent Biosciences' stock has soared after its lead asset, bezuclastinib plus sunitinib, outperformed sunitinib alone in a pivotal gastrointestinal cancer…
-
Dupixent set for ninth US approval after Phase III AFRS success
Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary…
-
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse event (AE). The…
-
Lilly to advance alternative obesity candidate to Phase III
Eli Lilly is advancing its obesity treatment candidate, which is an alternative to glucagon-like peptide-1 receptor agonists (GLP-1RAs), to Phase…